News

With the rise of a new generation of information technology and the development of many high-tech fields, a series of cutting-edge technologies represented by artificial intelligence has begun to shine in various traditional fields, of which the integration of artificial intelligence and pharmaceutical industry development is particularly noteworthy. Especially in pharmaceuticals, is constantly providing strong help.

Breakthrough infection (BTI) means that the novel coronavirus test results of the vaccinators are positive more than 14 days after the completion of vaccination. Previous studies have described the symptoms of long-term sequelae (i.e. long covid) after infection with COVID-19, but it is not clear whether breakthrough COVID-19 infection in vaccinated people will lead to related sequelae.

COVID-19 and influenza are both infectious respiratory diseases with some similar symptoms, but they are caused by different viruses and there are some differences in the characteristics of people who become seriously ill and in the way they are treated.

On 22 April 2022, a Friday evening, Hengrui, the “number one pharmaceutical company”, officially released its annual report, covering the company’s first negative growth in the past two decades. As a former leader in China’s pharmaceutical industry, Hengrui’s difficult transition is more of a painful exploration of the pharmaceutical industry in the process of breaking down the old and creating a new one.

Recent years, China has focused on the actual development of the medical device industry as well as the public demand for medical devices, and is continuously issuing favorable policies to promote the healthy and orderly development of the medical device industry.
At present, the domestic medical device industry has ushered in a broader space for development. At the same time, a large number of domestic innovative medical device products have started to emerge, and many medical behaviours have been changed by the emergence of new technologies and new products. In addition, a large number of medical device companies have also seen favourable performance.

In recent years, the market for neurological drugs is seeing further growth due to various influences. For example, the sales revenue of central nervous system drugs in China has increased from 144 billion yuan in 2015 to 204.3 billion yuan in 2019, with a compound annual growth rate of about 9%, and it is expected that this drug market is expected to reach 250.9 billion yuan by 2024.

In the pharmaceutical market, neurological drugs have always been one of the larger areas. It is understood that, in the sub-category pattern, the nervous system drugs mainly have psychostimulants, painkillers, anesthetics, psychostimulants, anti-epileptic drugs and other seven sub-categories.

The rare disease market has a large unmet clinical need, both in China and overseas. Data shows that the global rare disease market has continued to heat up in recent years, with the market for rare disease drugs reaching US$135.1 billion in 2020, and is expected to reach US$383.3 billion by 2030, with a compound annual growth rate of 11%.

Chinese medicine is a great creation of the Chinese nation, a treasure of ancient science in China, and has had a positive impact on the progress of the Chinese nation and the world’s civilisation, with its stable nature, precise efficacy, relatively small toxic side effects, and the convenience of taking, carrying and storing.

Recently, I saw someone a forum said: “the company trial production of a new variety of API, after drying, the completed material is as hard as stones, with a portable crusher effect is very poor, with a swing crusher machine and crusher have tried, but also still not.” So he asked, there is no good crushing equipment recommended?